Adamas Pharmaceuticals Expands Clinical Study for Triple-Combination Antiviral Drug Therapy in Immune-Compromised Patients
EMERYVILLE, Calif., Nov. 19 Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for influenza A, including novel influenza A/H1N1, the cause of the current flu pandemic. TCAD therapy consists of Adamas' proprietary combination of amantadine and ribavirin administered adjunctively with a neuraminidase inhibitor such as oseltamivir. The study is designed to assess the ability of TCAD therapy to suppress replication of the influenza A virus, alleviate symptoms from subjects and impede the development of resistance.
"Immune-compromised patients are at increased risk for life-threatening complications from influenza infection, and therefore the development of a broad-spectrum anti-influenza treatment is critical for this underserved population," said Gregory Went, Ph.D., Chief Executive Officer and Chairman of Adamas. "We have accelerated our development efforts to generate clinical data that demonstrate how TCAD therapy can address the needs of influenza patients in light of the prevalence of novel influenza A/H1N1 flu this season and growing concerns about the emergence of antiviral resistance during treatment with single neuraminidase inhibitors like oseltamivir."
The study, AAVID-1(TM) (Adamas Antiviral Influenza Drug), is a Phase 2, open-label, randomized study that will enroll during the 2009/10 influenza season up to 250 immune-compromised adults and children with influenza A in up to 45 study sites. The study's primary endpoint is the time to clearing of viral shedding. Study participants will include patients ages one to 65 who are immune-compromised due to receiving chemotherapy or immunosuppressive medications, or who are HIV positive. The protocol calls for study participants to be randomized to receive either the TCAD therapy comprised of amantadine and ribavirin with oseltamivir or oseltamivir monotherapy for 10 days. The follow-up period will be six months following treatment and an Independent Data Monitoring Committee will monitor the safety of participants throughout the duration of the study.
"There is a clear need for alternative antiviral strategies to treat influenza, especially for immune-compromised patients at risk for development of drug resistance and severe clinical outcomes," said Menno de Jong, M.D., Ph.D., professor in Clinical Virology at the Department of Medical Microbiology, Academic Medical Centre of the University of Amsterdam, and Chair of the Protocol Steering Committee for this Phase 2 trial. "Based on preclinical results showing that Adamas' triple combination of amantadine, ribavirin, and oseltamivir is synergistic in its ability to block replication of the influenza virus, I believe Adamas' approach has much potential, and look forward to being involved in this study."
For more information on the AAVID-1 trial, please visit www.clinicaltrials.gov or www.adamaspharma.com.
Adamas' TCAD therapy for influenza is designed to inhibit viral replication at multiple points during the virus life cycle. TCAD therapy includes Adamas' investigational combination of amantadine and ribavirin, to be administered adjunctively with a neuraminidase inhibitor. Preclinical data indicate that the in vitro combination of these drugs, each with their own mechanism of action, acts synergistically to provide a much higher level of antiviral activity than single or double drug combinations. In in vitro studies to date, TCAD therapy also has been found to provide greater antiviral activity across multiple strains of influenza, even those resistant to single pharmaceutical agents.
Adamas is an emerging pharmaceutical company focused on developing small molecule, Advantaged Therapeutics(TM) to treat neurological and infectious diseases, including influenza A, the cause of the current flu pandemic. Adamas' approach to pharmaceutical development is to identify synergistic drug mechanisms that can be developed as optimized combination drug therapies to increase safety, efficacy and compliance, thus improving upon the standard of care. Adamas is headquartered in Emeryville, California, with operations in Bangalore, India. For more information about Adamas, please visit www.adamaspharma.com.
SOURCE Adamas Pharmaceuticals, Inc.
You May Also Like